Lacosamide

Description Generic formulation Indications Dose titration Uses Side effects Cautions Interactions Special populations Behavioural and cognitive effects in patients with epilepsy Psychiatric use References

Product Name: Lacosamide
CAS No.: 175481-36-4
Chemical Name: Lacosamide
Synonyms: ViMpat;Erlosamide;Lacosamide API;(R)-2-Acetamido-N-benzyl-3-methoxypropanamide;(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide;SPM 927;ACOSAMIDE;LACOSAMIDE;ADD 243037;Lacoxamide
CBNumber: CB41011740
Molecular Formula: C13H18N2O3
Formula Weight: 250.29
MOL File: 175481-36-4.mol

More

Less

Lacosamide Property

Melting point:: 141-143?C
alpha: D23 +16.0° (c = 1 in CH3OH)
Boiling point:: 536.4±50.0 °C(Predicted)
Density: 1.120±0.06 g/cm3(Predicted)
Flash point:: 2℃
storage temp.: Refrigerator
solubility: DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 2 mg/ml
form: A crystalline solid
pka: 14.19±0.46(Predicted)
InChI: InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
InChIKey: VPPJLAIAVCUEMN-GFCCVEGCSA-N
SMILES: C(NCC1=CC=CC=C1)(=O)[C@H](NC(C)=O)COC
CAS DataBase Reference: 175481-36-4

More

Less

Safety

Hazard Codes: F,Xn
Risk Statements: 11-20/21/22-36
Safety Statements: 16-26-36/37
RIDADR: UN 1648 3 / PGII
WGK Germany: 2
HS Code: 2924296000

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H225Highly Flammable liquid and vapour

H319Causes serious eye irritation

Precautionary statements

P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: L-029
Product name: Lacosamide solution
Purity: 1.0?mg/mL in acetonitrile, ampule of 1?mL, certified reference material, Cerilliant?
Packaging: 1mL
Price: $202
Updated: 2024/03/01

Cayman Chemical

Product number: 10012592
Product name: Lacosamide
Purity: ≥98%
Packaging: 5mg
Price: $49
Updated: 2024/03/01

Cayman Chemical

Product number: 10012592
Product name: Lacosamide
Purity: ≥98%
Packaging: 10mg
Price: $87
Updated: 2024/03/01

Cayman Chemical

Product number: 10012592
Product name: Lacosamide
Purity: ≥98%
Packaging: 25mg
Price: $152
Updated: 2024/03/01

Cayman Chemical

Product number: 10012592
Product name: Lacosamide
Purity: ≥98%
Packaging: 50mg
Price: $278
Updated: 2024/03/01

More

Less

Lacosamide Chemical Properties,Usage,Production

Description

Lacosamide (LCM), (SPM 927, (R)-2-acetamido-N-benzyl-3-methoxypropionamide, previously referred to as harkoseride or ADD 234037) is a member of a series of functionalized amino acids that were specifically synthesized as anticonvulsant or antiepileptic drug. It reduces the spread of seizure activity in the brain. Lacosamide appears to have a dual mode of action: selective enhancement of sodium channel inactivation and modulation of collapsin response mediator protein-2. Compared to novel antiepileptic drugs, lacosamide has broader and higher efficacy, better tolerability, and improved pharmacokinetic properties. Lacosamide is in phase III clinical development for adjunctive treatment of patients with uncontrolled partial-onset seizures, and for monotherapy of patients with painful diabetic neuropathy. It is absorbed rapidly and completely after oral administration. Lacosamide has an elimination half-life of approximately 13 hours and a low potential for drug interactions. Additionally, lacosamide exhibits linear, dose-proportional pharmacokinetics with low intra- and interpatient variability.
Lacosamide (licensed in 2008) is a third- generation AED known with the proprietary brand name of Vimpat® (UCB Pharma, Slough) in the UK and USA.

Generic formulation

MHRA/ CHM advice to minimize risk when switching patients with epilepsy between different manufacturers’ products (incl. generic products):

It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific concerns, such as patient anxiety and risk of confusion/ dosing error.

Indications

Epilepsy: Adjunctive treatment of focal seizures with or without secondary generalization.

Dose titration

Epilepsy— adjunctive therapy: 50 mg bd for 7 days, then increased by 50 mg bd every 7 days; usual maintenance 100 mg bd (max. 200 mg bd).
Epilepsy— adjunctive therapy (loading dose regimen when it is necessary to rapidly attain therapeutic plasma concentrations, under close medical supervision): 200 mg bd for 1 day, followed by maintenance dose of 100 mg bd after 1 day, then increased if needed by 50 mg bd every 7 days (max. 200 mg bd).

Uses

Lacosamide is an anticonvulsant and analgesic compound used for the treatment of partial-onset seizures and neuropathic pain. It can also used for the treatment of status epilepticus. Its analgesic effect is mediated by its inhibitory effect on sodium channels, which leads to neural membrane depolarization. Its interaction with the collapsin-response mediator protein 2 (CRMP-2 alias DRP-2) may also facilitate the above process, although the detailed mechanism remains to be elucidated.

Side effects

Lacosamide was generally well tolerated in adult patients with partial-onset seizures.[11] The side-effects most commonly leading to discontinuation were dizziness, ataxia, diplopia (double vision), nystagmus, nausea, vertigo and drowsiness. These adverse reactions were observed in at least 10% of patients.[9] Less common side-effects include tremors, blurred vision, vomiting and headache.

Cautions

Patients with conduction problems (contraindicated in patients with second- or third- degree A– V block).
Patients with severe cardiac disease.
Patients at risk of PR- interval prolongation.
Elderly patients.

Interactions

With AEDs
Concomitant treatment with other AEDs known to be enzyme inducers (such as carbamazepine, phenobarbital, phenytoin) decreases the overall systemic exposure of lacosamide by 25%.

With other drugs
Nil.

With alcohol/food

Although no pharmacokinetic data on the interaction of lacosamide with alcohol are available, a pharmacodynamic effect cannot be excluded.
There are no specific foods that must be excluded from diet when taking lamotrigine.

Special populations

Hepatic impairment

Titrate with caution in mild- to- moderate impairment if co- existing renal impairment.
Caution in severe impairment.

Renal impairment

Loading dose regimen can be considered in mild- to- moderate impairment (titrate above 200 mg with caution).
Titrate with caution in severe impairment (max. 250 mg daily).

Pregnancy

There are no adequate data from the use of lacosamide in pregnant women and the potential risk for humans is unknown.
Lacosamide should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). If a woman decides to become pregnant, the use of lacosamide should be carefully re- evaluated. In case of treatment with lacosamide, the dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.
Lacosamide has been found to be present in milk in animal studies and it is recommended that it should be avoided during breastfeeding

Behavioural and cognitive effects in patients with epilepsy

For this third- generation agent, clinical experience is still limited and little is known about its positive and negative psychotropic properties and their implications for the management of behavioural symptoms in patients with epilepsy. There are initial reports of depression, irritability and agitation, and psychotic symptoms. Reports of cognitive effects (mainly affecting attention and memory) are rare and usually not severe.

Psychiatric use

Lacosamide has no indications for the treatment of psychiatric disorders. There is insufficient experience with lacosamide to draw any conclusion regarding its psychotropic profile.

References

[1] B. K. Beyreuther, J. Freitag, C. Heers, N. Krebsfänger, U. Scharfenecker, T. Stöhr (2007) Lacosamide: a review of preclinical properties, CNS Drug Reviews, 13, 21-42
[2] Beyreuther, Bettina K., et al. "Lacosamide: A Review of Preclinical Properties." Cns Drug Reviews 13.1(2007):21.
[3]Chung, S, et al. "Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial." Epilepsia 51.6(2010):958–967.
[4]Kellinghaus, C, et al. "Intravenous lacosamide for treatment of status epilepticus." Acta Neurologica Scandinavica 123.2(2011):137–141.

Description

Although epilepsy is a neurological disorder with varying etiology and severity, the common feature is unprovoked, recurring seizures. Whether classified as generalized, involving both cerebral hemispheres, or partial with only localized portions of brain participation at onset, effective treatment relies on accurate assessment of syndrome type to optimally decrease the frequency, duration, and severity of seizures. The latest weapon against partial onset epilepsy is lacosamide, formerly known as harkoseride and erlosamide. The data also indicate that lacosamide binds to collapsing response mediator protein 2 (CRMP2); CRMP2 is involved in neuronal differentiation, control of axonal outgrowth, and possibly epileptogenesis. Furthermore, lacosamide is heralded as having a dual mode of action as it has also displayed efficacy against diabetic neuropathy, possibly as a result of stabilization of neuronal hyperexcitability. Currently,lacosamide is approved as adjunctive treatment of partial onset seizures in patients 17 years or older and is in development as a monotherapy for epilepsy and for neuropathic pain.

Description

Lacosamide selectively enhances sodium channel slow inactivation without affecting fast inactivation. It is effective in multiple rodent models of seizure activity. The neuroprotective effects of lacosamide are also attributed to its ability to modulate collapsin response mediator protein 2 (CRMP-2), a member of the semaphorin signal transduction pathway. Formulations containing lacosamide have been used as an adjunctive or monotherapy for focal-onset seizures but, at higher doses, have a low potential for abuse. Lacosamide is regulated as a Schedule V compound in the United States.

Chemical Properties

White to Off-White Solid

Originator

Harris FRC (United States)

Uses

A potent anticonvulsant.

Definition

ChEBI: Lacosamide is a N-acyl-amino acid.

brand name

Vimpat

Synthesis

The most common adverse events were diplopia, headache, dizziness, and nausea. As typical with AEDs, lacosamide may increase the risk of suicidal thoughts or behavior. Patients should, therefore, be monitored for the emergence or worsening of depression. Caution should also be exercised in patients with known conduction problems or severe cardiac disease (myocardial ischemia or heart failure) since dose-dependent prolongations in PR interval have been observed in clinical studies.

Lacosamide Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Lacosamide Suppliers

Argentina 1 Brazil 1 Canada 6 China 320 Czech Republic 2 France 2 Germany 2 Greece 1 Hungary 1 India 120 Israel 1 Italy 1 Nepal 1 South Africa 1 Spain 1 The Netherlands 1 United Arab Emirates 1 United Kingdom 8 United States 32 Global 503

LGM Pharma

Tel: 1-(800)-881-8210
Fax: 615-250-9817
Email: inquiries@lgmpharma.com
Country: United States
ProdList: 2123
Advantage: 70

AdooQ BioScience, LLC

Tel: +1 (866) 930-6790
Fax: +1 (866) 333-9607
Email: info@adooq.com
Country: United States
ProdList: 2782
Advantage: 58

Target molecule Corp.

Tel: 857-239-0968
Fax: 857-239-8801
Email: service1@targetmol.com
Country: United States
ProdList: 2559
Advantage: 60

Alfa Chemistry

Tel
Fax: 1-516-927-0118
Email: Info@alfa-chemistry.com
Country: United States
ProdList: 24072
Advantage: 58

Cato Research Chemicals Inc.

Tel: 020-81215950 4000-868-328
Email: customer@uwalab.com
Country: United States
ProdList: 10404
Advantage: 58

Alchem Pharmtech,Inc.

Tel: 8485655694
Email: sales@alchempharmtech.com
Country: United States
ProdList: 63687
Advantage: 58

TargetMol Chemicals Inc.

Tel: +8613564774135
Email: zijue.cai@tsbiochem.com
Country: United States
ProdList: 19885
Advantage: 58

Protheragen-ING

Tel: +16313385890
Email: info@protheragen-ing.com
Country: United States
ProdList: 3868
Advantage: 58

Cayman Chemical Company

Tel: --
Fax: --
Email: cayman@caymanchem.com
Country: United States
ProdList: 6213
Advantage: 81

Parchem Fine & Specialty Chemicals

Tel: --
Fax: --
Email: info@parchem.com
Country: United States
ProdList: 1031
Advantage: 58

Jubilant Pharma Holdings Inc.

Tel: --
Fax: --
Email: bd.api@jubl.com
Country: United States
ProdList: 39
Advantage: 58

Kare Bay Biochem Inc.

Tel: --
Fax: --
Email: product@karebaybio.com
Country: United States
ProdList: 110
Advantage: 58

Glentham Life Sciences Ltd

Tel: --
Fax: --
Email: info@glentham.com
Country: United States
ProdList: 2026
Advantage: 58

MilliporeSigma (Sigma-Aldrich Corp.)

Tel: --
Fax: --
Email: @sial.com
Country: United States
ProdList: 5414
Advantage: 58

R&S Chemicals, Inc.

Tel: --
Fax: --
Email: info@randschemicals.com
Country: United States
ProdList: 13
Advantage: 58

MedKoo Biosciences, Inc.

Tel: --
Fax: --
Email: sales@medkoo.com
Country: United States
ProdList: 126
Advantage: 58

SHAMROCK INDUSTRIAL CO. LTD.

Tel: --
Fax: --
Email: pharma@shamrockindia.com
Country: United States
ProdList: 119
Advantage: 43

PlusPharma Incorporated

Tel: --
Fax: --
Email: info@pluspharm.com
Country: United States
ProdList: 53
Advantage: 58

TOPCHEM PHARMACEUTICALS LTD

Tel: --
Fax: --
Email: Vinchem@vinchem.com
Country: United States
ProdList: 140
Advantage: 58

SynInnova Laboratories Inc.

Tel: --
Fax: --
Email: sales@syninnova.com
Country: United States
ProdList: 491
Advantage: 50

SST Corporation

Tel: --
Fax: --
Email: info@sst-corp.com
Country: United States
ProdList: 237
Advantage: 38

ACIC Fine Chemicals Inc.

Tel: --
Fax: --
Email: sales@acic.com
Country: United States
ProdList: 492
Advantage: 48

Hikal Ltd.

Tel: --
Fax: --
Email: hr@hikal.com
Country: United States
ProdList: 25
Advantage: 77

Cerilliant Corporation

Tel: --
Fax: --
Email: techserv@cerilliant.com
Country: United States
ProdList: 1629
Advantage: 69

EUTICALS INC

Tel: --
Fax: --
Country: United States
ProdList: 6
Advantage: 58

Riedel-de Haen AG

Tel: --
Fax: --
Country: United States
ProdList: 6773
Advantage: 87

Chemlex Pharmaceuticals LLC

Tel: --
Fax: --
Email: chemlexpharma@yahoo.com
Country: United States
ProdList: 238
Advantage: 0

CacheSyn Inc.

Tel: --
Fax: --
Email: info@cachesyn.com
Country: United States
ProdList: 695
Advantage: 50

SynFine Research

Tel: --
Fax: --
Email: research@synfine.com
Country: United States
ProdList: 1024
Advantage: 68

Selleck Chemicals LLC

Tel: --
Fax: --
Email: info@selleckchem.com
Country: United States
ProdList: 824
Advantage: 60

Ivy Fine Chemicals

Tel: --
Fax: --
Email: sales@ivychem.com
Country: United States
ProdList: 6493
Advantage: 58

Medical Isotopes

Tel: --
Fax: --
Email: stohler@medicalisotopes.com
Country: United States
ProdList: 6181
Advantage: 68

More

Less

View Lastest Price from Lacosamide manufacturers

Sinoway Industrial co., ltd.

Product: Lacosamide 175481-36-4
Price: US $0.00/Kg/Bag
Min. Order: 2Kg/Bag
Purity: 99% up, High Density
Supply Ability: 20 tons
Release date: 2022-07-19

WUHAN FORTUNA CHEMICAL CO., LTD

Product: Lacosamide 175481-36-4
Price: US $0.00/KG
Min. Order: 1KG
Purity: 98.0%
Supply Ability: 100kg/month
Release date: 2022-12-28

Hebei Yanxi Chemical Co., Ltd.

Product: LACOSAMIDE 175481-36-4
Price: US $30.00-1.00/kg
Min. Order: 1kg
Purity: 0.99
Supply Ability: 20 tons
Release date: 2023-11-23

175481-36-4, LacosamideRelated Search:

Febuxostat LacosaMide iMpurity 2-(Acetylamino)-N-(phenylmethyl)-2-propenamide (S)-2-Acetamido-N-benzyl-3-methoxypropanamide (R)-O-Acetyl-LacosaMide Benzylamine hydrochloride (R)-2-amino-N-benzyl-3-methoxypropanamide Desmethyl Lacosamide Lacosamide EP impurity I Lacosamide EP impurity G Lacosamide EP impurity B Lacosamide EP impurity J Lacosamide EP impurity E Lacosamide EP impurity F Lacosamide EP impurity A Propionamide Avoparcin LACOSAMIDE

LACOSAMIDE

(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide

(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide

ADD 243037

Erlosamide

Harkoseride

SPM 927

(R)-2-Acetamido-N-benzyl-3-methoxypropanamide

Lacosamide-d3 (Acetyl-d3)

ViMpat

(2R)-N-benzyl-2-acetaMido-3-MethoxypropanaMide

LacosaMide (1.0Mg/ML in Acetonitrile)

(R)-2-Acetamido-N-benzyl-3-methoxypropionamide

Lacosamide solution

(2R)-2-ACETAMIDO-3-METHOXY-N-(PHENYLMETHYL)PROPANAMIDE

(R)-2-acetamido-N-benzyl-3-_x001f_methoxypropionamide

Lacosamide API

Lacosamide CRS

Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-

Can sand meters

LACOSAMIDE USP/EP/BP

2R-(acetylamino)-3-methoxy-N-(phenylmethyl)-propanamide

LACOSAMIDE (Y0001982)

Lacosamide for system suitability (Y0001973)

LacosamideQ: What is Lacosamide Q: What is the CAS Number of Lacosamide Q: What is the storage condition of Lacosamide Q: What are the applications of Lacosamide

Lacosamide for system suitability CRS (Y0001973)

Propanoicacid,7-methyl-,tetradecylester

Lacoxamide

Lacosamide solution iMpurity

Lacosamide (2R)-2-(Acetylamino)-3-methoxy-N- (phenylmethyl)propanamide

Lacosamine

Lecosamide Reference Standard

Lacosamidc

ACOSAMIDE

175481-36-4

Inhibitors

Other APIs

API

Pharmaceutical raw material

Amino Acids 13C, 2H, 15N

Amino Acids & Derivatives

Intermediates & Fine Chemicals

Pharmaceuticals

175481-36-4